The US FDA conducted an inspection at Gland Pharma Ltd s API Facility at JNPC, Visakhapatnam from 23rd January, 2023 to 27th January, 2023 and has been completed with Zero observation.
The Board of Directors of Gland Pharma Limited, at its meeting held today have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23 and 9MFY23.
Gland Pharma Ltd has announced about the Pre-Market Inspection covering US FDA s Quality System / Current Good Manufacturing Practice regulations for Medical Devices i.e., 21 CFR Part 820 at Dundigal Facility at Hyderabad.
Gland Pharma Ltdhas through its wholly owned subsidiary Gland Pharma International PTE. Ltd, Singapore entered into a Put Option Agreement to acquire 100% of Cenexi Group for an Equity Value not exceeding Euro 120 Mn.
The Board of Directors of Gland Pharma Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2022 - Q2FY23 and H1FY23.